Forest Laboratories submits Cariprazine drug application: Richter

BUDAPEST (Reuters) - Forest Laboratories has recently submitted a new drug application to the U.S. Food and Drug Administration (FDA) for antipsychotic drug Cariprazine, its Hungarian partner Richter said in a statement on Wednesday.

Cariprazine was discovered by Richter and is licensed to Forest Laboratories Inc. in the U.S. and Canada.

Richter said Forest's application to the FDA was submitted for the treatment of both schizophrenia and manic or mixed episodes associated with bipolar I disorder.

(Reporting by Gergely Szakacs; Editing by David Goodman)